Skip to contentR
Regenxbio Inc.
R
RGNXRegenxbio Inc. Q3 2023 · 10-Q
Revenue$28.91M$28.91M+9.1% vs Q3 2022 Net Income-$61.87M-$61.87MN/M vs Q3 2022 EPS Diluted-$1.41-$1.41N/M vs Q3 2022 Operating Income-$64,960,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Regenxbio Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$50,846,000N/M Margins · derivedOperating margin-224.7%+43.3 pt vs Q3 2022
Net margin-214.0%+70.7 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 8, 2023 · 39 d after period end